308 related articles for article (PubMed ID: 28334834)
1. AAV-mediated transfer of FKRP shows therapeutic efficacy in a murine model but requires control of gene expression.
Gicquel E; Maizonnier N; Foltz SJ; Martin WJ; Bourg N; Svinartchouk F; Charton K; Beedle AM; Richard I
Hum Mol Genet; 2017 May; 26(10):1952-1965. PubMed ID: 28334834
[TBL] [Abstract][Full Text] [Related]
2. Autologous intramuscular transplantation of engineered satellite cells induces exosome-mediated systemic expression of Fukutin-related protein and rescues disease phenotype in a murine model of limb-girdle muscular dystrophy type 2I.
Frattini P; Villa C; De Santis F; Meregalli M; Belicchi M; Erratico S; Bella P; Raimondi MT; Lu Q; Torrente Y
Hum Mol Genet; 2017 Oct; 26(19):3682-3698. PubMed ID: 28666318
[TBL] [Abstract][Full Text] [Related]
3. Muscle and heart function restoration in a limb girdle muscular dystrophy 2I (LGMD2I) mouse model by systemic FKRP gene delivery.
Qiao C; Wang CH; Zhao C; Lu P; Awano H; Xiao B; Li J; Yuan Z; Dai Y; Martin CB; Li J; Lu Q; Xiao X
Mol Ther; 2014 Nov; 22(11):1890-9. PubMed ID: 25048216
[TBL] [Abstract][Full Text] [Related]
4. Adeno-associated virus 9 mediated FKRP gene therapy restores functional glycosylation of α-dystroglycan and improves muscle functions.
Xu L; Lu PJ; Wang CH; Keramaris E; Qiao C; Xiao B; Blake DJ; Xiao X; Lu QL
Mol Ther; 2013 Oct; 21(10):1832-40. PubMed ID: 23817215
[TBL] [Abstract][Full Text] [Related]
5. Fukutin-related protein is essential for mouse muscle, brain and eye development and mutation recapitulates the wide clinical spectrums of dystroglycanopathies.
Chan YM; Keramaris-Vrantsis E; Lidov HG; Norton JH; Zinchenko N; Gruber HE; Thresher R; Blake DJ; Ashar J; Rosenfeld J; Lu QL
Hum Mol Genet; 2010 Oct; 19(20):3995-4006. PubMed ID: 20675713
[TBL] [Abstract][Full Text] [Related]
6. Post-Natal knockdown of fukutin-related protein expression in muscle by long-termRNA interference induces dystrophic pathology [corrected].
Wang CH; Chan YM; Tang RH; Xiao B; Lu P; Keramaris-Vrantsis E; Zheng H; Qiao C; Jiang J; Li J; Ma HI; Lu Q; Xiao X
Am J Pathol; 2011 Jan; 178(1):261-72. PubMed ID: 21224063
[TBL] [Abstract][Full Text] [Related]
7. Zebrafish models for human FKRP muscular dystrophies.
Kawahara G; Guyon JR; Nakamura Y; Kunkel LM
Hum Mol Genet; 2010 Feb; 19(4):623-33. PubMed ID: 19955119
[TBL] [Abstract][Full Text] [Related]
8. A New Mouse Model of Limb-Girdle Muscular Dystrophy Type 2I Homozygous for the Common L276I Mutation Mimicking the Mild Phenotype in Humans.
Krag TO; Vissing J
J Neuropathol Exp Neurol; 2015 Dec; 74(12):1137-46. PubMed ID: 26574668
[TBL] [Abstract][Full Text] [Related]
9. Efficient engraftment of pluripotent stem cell-derived myogenic progenitors in a novel immunodeficient mouse model of limb girdle muscular dystrophy 2I.
Azzag K; Ortiz-Cordero C; Oliveira NAJ; Magli A; Selvaraj S; Tungtur S; Upchurch W; Iaizzo PA; Lu QL; Perlingeiro RCR
Skelet Muscle; 2020 Apr; 10(1):10. PubMed ID: 32321586
[TBL] [Abstract][Full Text] [Related]
10. Residual laminin-binding activity and enhanced dystroglycan glycosylation by LARGE in novel model mice to dystroglycanopathy.
Kanagawa M; Nishimoto A; Chiyonobu T; Takeda S; Miyagoe-Suzuki Y; Wang F; Fujikake N; Taniguchi M; Lu Z; Tachikawa M; Nagai Y; Tashiro F; Miyazaki J; Tajima Y; Takeda S; Endo T; Kobayashi K; Campbell KP; Toda T
Hum Mol Genet; 2009 Feb; 18(4):621-31. PubMed ID: 19017726
[TBL] [Abstract][Full Text] [Related]
11. Limb girdle muscular dystrophy type 2I: No correlation between clinical severity, histopathology and glycosylated α-dystroglycan levels in patients homozygous for common FKRP mutation.
Alhamidi M; Brox V; Stensland E; Liset M; Lindal S; Nilssen Ø
Neuromuscul Disord; 2017 Jul; 27(7):619-626. PubMed ID: 28479227
[TBL] [Abstract][Full Text] [Related]
12. Adeno-associated virus-mediated overexpression of LARGE rescues α-dystroglycan function in dystrophic mice with mutations in the fukutin-related protein.
Vannoy CH; Xu L; Keramaris E; Lu P; Xiao X; Lu QL
Hum Gene Ther Methods; 2014 Jun; 25(3):187-96. PubMed ID: 24635668
[TBL] [Abstract][Full Text] [Related]
13. Ribitol restores functionally glycosylated α-dystroglycan and improves muscle function in dystrophic FKRP-mutant mice.
Cataldi MP; Lu P; Blaeser A; Lu QL
Nat Commun; 2018 Aug; 9(1):3448. PubMed ID: 30150693
[TBL] [Abstract][Full Text] [Related]
14. Impaired viability of muscle precursor cells in muscular dystrophy with glycosylation defects and amelioration of its severe phenotype by limited gene expression.
Kanagawa M; Yu CC; Ito C; Fukada S; Hozoji-Inada M; Chiyo T; Kuga A; Matsuo M; Sato K; Yamaguchi M; Ito T; Ohtsuka Y; Katanosaka Y; Miyagoe-Suzuki Y; Naruse K; Kobayashi K; Okada T; Takeda S; Toda T
Hum Mol Genet; 2013 Aug; 22(15):3003-15. PubMed ID: 23562821
[TBL] [Abstract][Full Text] [Related]
15. Reduced expression of fukutin related protein in mice results in a model for fukutin related protein associated muscular dystrophies.
Ackroyd MR; Skordis L; Kaluarachchi M; Godwin J; Prior S; Fidanboylu M; Piercy RJ; Muntoni F; Brown SC
Brain; 2009 Feb; 132(Pt 2):439-51. PubMed ID: 19155270
[TBL] [Abstract][Full Text] [Related]
16. Four-week rapamycin treatment improves muscular dystrophy in a fukutin-deficient mouse model of dystroglycanopathy.
Foltz SJ; Luan J; Call JA; Patel A; Peissig KB; Fortunato MJ; Beedle AM
Skelet Muscle; 2016; 6():20. PubMed ID: 27257474
[TBL] [Abstract][Full Text] [Related]
17. FKRP gene mutations cause congenital muscular dystrophy, mental retardation, and cerebellar cysts.
Topaloglu H; Brockington M; Yuva Y; Talim B; Haliloglu G; Blake D; Torelli S; Brown SC; Muntoni F
Neurology; 2003 Mar; 60(6):988-92. PubMed ID: 12654965
[TBL] [Abstract][Full Text] [Related]
18. Improved efficacy of FKRP AAV gene therapy by combination with ribitol treatment for LGMD2I.
Cataldi MP; Vannoy CH; Blaeser A; Tucker JD; Leroy V; Rawls R; Killilee J; Holbrook MC; Lu QL
Mol Ther; 2023 Dec; 31(12):3478-3489. PubMed ID: 37919902
[TBL] [Abstract][Full Text] [Related]
19. Functional requirements for fukutin-related protein in the Golgi apparatus.
Esapa CT; Benson MA; Schröder JE; Martin-Rendon E; Brockington M; Brown SC; Muntoni F; Kröger S; Blake DJ
Hum Mol Genet; 2002 Dec; 11(26):3319-31. PubMed ID: 12471058
[TBL] [Abstract][Full Text] [Related]
20. A limb-girdle muscular dystrophy 2I model of muscular dystrophy identifies corrective drug compounds for dystroglycanopathies.
Serafini PR; Feyder MJ; Hightower RM; Garcia-Perez D; Vieira NM; Lek A; Gibbs DE; Moukha-Chafiq O; Augelli-Szafran CE; Kawahara G; Widrick JJ; Kunkel LM; Alexander MS
JCI Insight; 2018 Sep; 3(18):. PubMed ID: 30232282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
